4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

Study Description
Brief Summary:
The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist. This is a small PI-initiated uncontrolled pilot study to gather safety and feasibility data on the exoskeleton in individuals with MS and walking impairment.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Gait Disorders, Neurologic Device: Ekso GT™ exoskeleton Not Applicable

Detailed Description:

Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some improvements in sitting, standing and walking posture when used consistently. The investigator is not aware of any study of the Ekso GT™ exoskeleton in MS.

This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5). Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients with MS.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
Actual Study Start Date : July 23, 2019
Actual Primary Completion Date : January 9, 2020
Actual Study Completion Date : January 9, 2020
Arms and Interventions
Arm Intervention/treatment
gait training with exoskeleton device
uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Device: Ekso GT™ exoskeleton
The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.

Outcome Measures
Primary Outcome Measures :
  1. Dropout Rate [ Time Frame: 0-14 weeks ]
    Percentage of enrolled participants who drop out of the study before the end of the treatment period.

  2. Adverse Events [ Time Frame: 0-14 weeks ]
    .All adverse events were collected throughout the study for each participant, up to 14 weeks",


Secondary Outcome Measures :
  1. Timed 25 Foot Walk [ Time Frame: 0-14 weeks ]
    Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of MS per 2017 revised McDonald criteria
  • EDSS score 5.5-7.5 (moderate to severe walking disability)
  • Cleared for gait training with the study device by the study treating physician

Device-Specific Criteria

  • Involved in a standing program or must be able to tolerate at least 15 min upright without signs or symptoms of orthostatic hypotension
  • Weigh 220 pounds (100kg) or less
  • Be able to fit into the Ekso device:
  • Between approximately 5'0" and 6'4" tall (really depends on leg measurements)
  • Sufficient diaphragmatic strength such that respiration is not compromised with exercise

Assessed by physical therapy:

  • Standing hip width of approximately 18" or less
  • Have near normal range of motion(ROM) in hips, knees and ankles
  • Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension of 4/5 OR as discussed during demo, 2 normally functioning limbs such as in hemiplegia)

Exclusion Criteria:

  • • MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to enrollment

    • Diagnosed with osteoporosis or history of long bone fractures since diagnosis
    • Safety concern due to neurologic impairments (e.g. upper extremity weakness, visual loss) or comorbidities (e.g. cardiac, respiratory)
    • Other neurologic or non-neurologic condition interfering with walking
    • < 1 month since previous intensive gait training regimen or initiation of treatment that can affect walking (e.g. medication for spasticity)
    • Planned change in medications that may affect walking during the study period
    • Uncontrolled or severe orthostatic hypotension that limits standing tolerance
    • Active heterotrophic ossification (HO), hip dysplasia, or uncontrolled hip/knee axis abnormalities
    • Score <22 on the Mini-Mental State Examination or deemed to have cognitive impairment precluding safe training with the device during the screening and training process
    • Colostomy
    • Pregnancy
    • Unresolved deep vein thrombosis
    • Uncontrolled autonomic dysreflexia
    • Currently involved in another rehabilitation study

Assessed by physical therapy:

  • Severe spasticity that prevents joint motion (severe stiffness or rigidity) in proximal lower extremity muscles, including hip adductors and knee flexors/extensors.
  • Hip flexion contracture greater than ~17°
  • Knee flexion contracture greater than 12°
  • Unable to achieve neutral ankle dorsiflexion with passive stretch (achieve neutral with up to 12° knee flexion)
  • Leg length discrepancy greater than 0.5" for upper leg, greater than 0.75" for lower leg
  • Spinal instability
  • Severe muscular or skeletal pain
  • Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness
  • Shoulder extension range of motion(ROM) < 50° excludes using crutches during sit to stand or vice versa. (Walking with crutches permitted, sit <> stand would be done with walker
Contacts and Locations

Locations
Layout table for location information
United States, Ohio
Cleveland Clinic Neurological Institute Mellen Center
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Layout table for investigator information
Principal Investigator: Francois A Bethoux, MD The Cleveland Clinic
Tracking Information
First Submitted Date  ICMJE June 6, 2019
First Posted Date  ICMJE June 27, 2019
Results First Submitted Date  ICMJE February 25, 2020
Results First Posted Date  ICMJE April 7, 2020
Last Update Posted Date April 7, 2020
Actual Study Start Date  ICMJE July 23, 2019
Actual Primary Completion Date January 9, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 26, 2020)
  • Dropout Rate [ Time Frame: 0-14 weeks ]
    Percentage of enrolled participants who drop out of the study before the end of the treatment period.
  • Adverse Events [ Time Frame: 0-14 weeks ]
    .All adverse events were collected throughout the study for each participant, up to 14 weeks",
Original Primary Outcome Measures  ICMJE
 (submitted: June 26, 2019)
  • Dropout Rate [ Time Frame: 0-14 weeks ]
    Percentage of enrolled participants who drop out of the study before the end of the treatment period.
  • Adverse Events [ Time Frame: 0-14 weeks ]
    Number of participants with adverse events occurring during or between treatment sessions.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 26, 2019)
Timed 25 Foot Walk [ Time Frame: 0-14 weeks ]
Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
Official Title  ICMJE Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
Brief Summary The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist. This is a small PI-initiated uncontrolled pilot study to gather safety and feasibility data on the exoskeleton in individuals with MS and walking impairment.
Detailed Description

Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some improvements in sitting, standing and walking posture when used consistently. The investigator is not aware of any study of the Ekso GT™ exoskeleton in MS.

This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5). Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients with MS.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Multiple Sclerosis
  • Gait Disorders, Neurologic
Intervention  ICMJE Device: Ekso GT™ exoskeleton
The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
Study Arms  ICMJE gait training with exoskeleton device
uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Intervention: Device: Ekso GT™ exoskeleton
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 26, 2019)
5
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 9, 2020
Actual Primary Completion Date January 9, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of MS per 2017 revised McDonald criteria
  • EDSS score 5.5-7.5 (moderate to severe walking disability)
  • Cleared for gait training with the study device by the study treating physician

Device-Specific Criteria

  • Involved in a standing program or must be able to tolerate at least 15 min upright without signs or symptoms of orthostatic hypotension
  • Weigh 220 pounds (100kg) or less
  • Be able to fit into the Ekso device:
  • Between approximately 5'0" and 6'4" tall (really depends on leg measurements)
  • Sufficient diaphragmatic strength such that respiration is not compromised with exercise

Assessed by physical therapy:

  • Standing hip width of approximately 18" or less
  • Have near normal range of motion(ROM) in hips, knees and ankles
  • Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension of 4/5 OR as discussed during demo, 2 normally functioning limbs such as in hemiplegia)

Exclusion Criteria:

  • • MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to enrollment

    • Diagnosed with osteoporosis or history of long bone fractures since diagnosis
    • Safety concern due to neurologic impairments (e.g. upper extremity weakness, visual loss) or comorbidities (e.g. cardiac, respiratory)
    • Other neurologic or non-neurologic condition interfering with walking
    • < 1 month since previous intensive gait training regimen or initiation of treatment that can affect walking (e.g. medication for spasticity)
    • Planned change in medications that may affect walking during the study period
    • Uncontrolled or severe orthostatic hypotension that limits standing tolerance
    • Active heterotrophic ossification (HO), hip dysplasia, or uncontrolled hip/knee axis abnormalities
    • Score <22 on the Mini-Mental State Examination or deemed to have cognitive impairment precluding safe training with the device during the screening and training process
    • Colostomy
    • Pregnancy
    • Unresolved deep vein thrombosis
    • Uncontrolled autonomic dysreflexia
    • Currently involved in another rehabilitation study

Assessed by physical therapy:

  • Severe spasticity that prevents joint motion (severe stiffness or rigidity) in proximal lower extremity muscles, including hip adductors and knee flexors/extensors.
  • Hip flexion contracture greater than ~17°
  • Knee flexion contracture greater than 12°
  • Unable to achieve neutral ankle dorsiflexion with passive stretch (achieve neutral with up to 12° knee flexion)
  • Leg length discrepancy greater than 0.5" for upper leg, greater than 0.75" for lower leg
  • Spinal instability
  • Severe muscular or skeletal pain
  • Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness
  • Shoulder extension range of motion(ROM) < 50° excludes using crutches during sit to stand or vice versa. (Walking with crutches permitted, sit <> stand would be done with walker
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04000373
Other Study ID Numbers  ICMJE 19-580
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Francois Bethoux, MD, The Cleveland Clinic
Study Sponsor  ICMJE The Cleveland Clinic
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Francois A Bethoux, MD The Cleveland Clinic
PRS Account The Cleveland Clinic
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP